Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Идёт Россия Набор открыт

D8400R00003

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia (HPP) in Children and Adults in Russia

Номер протоколаD8400R00003
ФазаФаза не указана
Участников по плану — во всех странах исследования55
Сроки29.12.2025 — 30.06.2030
Начало: 29 декабря 2025Окончание: 30 июня 2030
Пройдено 20% планового срока

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07390240/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Исследование идёт, в реестре указано, что набор участников открыт.
  • Возраст участников: любой. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 55 чел. во всех странах исследования.
  • Плановое окончание — 06.2030.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастлюбой
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 6

Критерии включения

  • Age ≥4 to <18 years, or ≥18 years at the time of enrollment;
  • Signed ICF for patients ≥18 years, or legal representatives (parents) of patients aged ≥4 to <18 years;
  • Written informed assent (for patients aged ≥14 to <18 years only);
  • No history of HPP treatment with enzyme-replacement therapy;
  • Diagnosis of symptomatic HPP confirmed by the presence of ALL of the following criteria:
  • reduced alkaline phosphatase (ALP) activity relative to age- and sex-specific reference ranges, confirmed by at least two separate measurements;
  • the identification of a monoallelic pathogenic, likely pathogenic, or variant of uncertain significance in the ALPL gene on genetic testing;
  • presence of clinically relevant manifestations*, consistent with HPP, confirmed by at least one of the following: i. Musculoskeletal pain requiring medical intervention or limiting activities of daily living, present at screening or documented within the previous 12 months (e.g., based on medical records, functional test results, treatment prescriptions and/or rehabilitation interventions); chronic or recurrent pain lasting ≥3 months may be considered based on medical history beyond the 12-month period prior to screening, provided appropriate documentation is available; ii. Muscle weakness and/or reduced physical function (e.g., impaired mobility, increased fatigue), present at screening or documented within the previous 12 months (e.g., based on medical records, functional test results, treatment prescriptions and/or rehabilitation interventions); iii. History of fractures, pseudofractures, or delayed fracture healing, confirmed by medical documentation and/or imaging studies performed within 24 months prior to screening (provided no subsequent interventions have occurred that may have altered the findings; if such interventions have occurred, repeat imaging may be performed at the investigator's discretion, if applicable within routine clinical practice); iv. Skeletal abnormalities (e.g., radiographic signs of rickets/osteomalacia), confirmed by medical documentation and/or imaging studies performed within 24 months prior to screening (provided no subsequent interventions have occurred that may have altered the findings; if such interventions have occurred, repeat imaging may be performed at the investigator's discretion, if applicable within routine clinical practice); v. Dental manifestations (e.g., premature loss of deciduous teeth with intact roots before the age of 5 years without significant trauma), confirmed by medical and/or dental records; vi. Limitation in mobility, endurance, or activities of daily living, present at screening or documented within the previous 12 months based on routine clinical assessment using questionnaires, scales, functional tests and/or other relevant clinical tools used in routine practice; such tools may include, for example, the 6-minute walk test (6MWT), Timed Up-and-Go test, Chair-Rise test, Borg scale, IPAQ, PedsQL, EQ 5D-3L, bioimpedance measurements, and other methods used in routine clinical practice; if symptoms are present at screening, confirmation may be based on clinical assessments performed within 3 months prior to screening (provided there are no clinically significant changes in the patient's condition) or at the screening visit; vii. Need for analgesics, physiotherapy, and/or other supportive care for clinical manifestations of HPP, present at screening or during the period prior to screening, confirmed by at least one of the following criteria (based on medical records):
  • regular use of analgesics (≥3 times per week for at least 4 consecutive weeks) within the previous 6 months, or escalation of analgesic therapy within the previous 6 months;
  • ≥1 structured course of physiotherapy and/or rehabilitation interventions prescribed for musculoskeletal manifestations of HPP within the previous 12 months, or ongoing sessions according to specialist recommendations;
  • use of non-pharmacological and/or medical measures to reduce symptoms and support function, including orthoses, insoles, assistive devices, local injections, or other symptomatic interventions; viii. Other clinical manifestations associated with HPP, in the investigator's opinion, present at screening or documented within the previous 12 months (based on clinical assessment and/or medical records).

Критерии невключения

  • Confirmed conditions presenting with clinical features overlapping with HPP, including but not limited to: cerebral palsy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy (Erb Roth dystrophy), acquired secondary myopathies of various etiologies;
  • Current participation in any clinical study (patients participating in other non interventional studies may be included);
  • Homozygous or compound heterozygous mutation in the ALPL gene;
  • Monoallelic pathogenic, likely pathogenic, or variant of uncertain significance in the ALPL gene in the absence of clinically relevant manifestations of HPP at the time of screening and/or in medical history consistent with the inclusion criterion #5;
  • In the opinion of the investigator, the patient is not able to return for follow-up visits or obtain required follow-up studies;
  • Pregnant and breastfeeding women.

Источник: ClinicalTrials.gov, NCT07390240 · запись обновлена в реестре 28 сентября 2026.

Дизайн и результаты

ДизайнНаблюдательное
Участников по плану (все страны)55
Результатыбудут после окончания
Что измеряют — первичные конечные точки (10)
  • (1) Mean age (in full years) at the HPP diagnosis; — Day 0 (Visit 1)
  • (2) Mean age at the onset of initial HPP symptoms (including separately any, skeletal, and non-skeletal symptoms); — Day 0 (Visit 1)
  • (3) Proportions of male and female patients — Day 0 (Visit 1)
  • (4) Proportions of adults and children at baseline (childhood- and adult-onset HPP); — Day 0 (Visit 1)
  • (5) Proportion of patients with a family history of HPP in a first-degree relative — Day 0 (Visit 1)
  • (6) Proportions of patients with specific skeletal and non-skeletal manifestation locations/sites affected at baseline: — Day 0 (Visit 1)
  • (7) Proportions of patients with history and/or presence of specific skeletal manifestations at baseline: — Day 0 (Visit 1)
  • (8) Proportions of patients with history and/or presence of specific dental manifestations at baseline: — Day 0 (Visit 1)
  • (9) Proportions of patients with history and/or presence of specific muscular manifestations at baseline: — Day 0 (Visit 1)
  • (10) Proportions of patients with history and/or presence of specific rheumatologic manifestations at baseline: — Day 0 (Visit 1)

Цель исследования

The effect of monoallelic variants in the ALPL gene on the natural course of hypophosphatasia (HPP) in children and adults in Russia (ATLANTIS)

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07390240 Официальный реестр (США) · загружено 9 ноября 2026
    Номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.